

January 7, 2025  
Mitsubishi Tanabe Pharma Corporation

Sub-licensing Agreement for the Oral Spleen Tyrosine Inhibitor Fostamatinib in Taiwan  
with Kissei Pharmaceutical

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura, "MTPC"), a member of the Mitsubishi Chemical Group, announced today that Tai Tien Pharmaceuticals Co., Ltd. (Head Office: Taipei, Taiwan; General Manager Tony Chu; "Tai Tien"), which is a consolidated subsidiary of MTPC, has entered into a sub-license agreement with Kissei Pharmaceutical Co., Ltd. (Head Office: Matsumoto, Nagano, Japan; Chairman and CEO: Mutsuo Kanzawa; "Kissei") to license development and commercialization rights in Taiwan for fostamatinib disodium hexahydrate ("this product"), a spleen tyrosine kinase (SYK) inhibitor.

This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion, thereby improving the bleeding symptoms caused by chronic idiopathic thrombocytopenic purpura (ITP).

By executing this agreement, Tai Tien will gain the rights to develop and commercialize this product in Taiwan and will pay Kissei an upfront payment and milestones based on the progress of commercialization. Kissei will supply the formulation to Tai Tien.

More than 60 years, based on the pharmaceutical development and sales foundation in Taiwan, MTPC has been focusing on cardiovascular diseases and metabolism, as well as autoimmune diseases. Through our own products and partnerships with other companies, MTPC contributes to patients by delivering a wide range of treatments in Taiwan.

*Contact:*

Mitsubishi Tanabe Pharma Corporation  
Pharma Business Strategy Division  
PR Department  
+81-6-6205-5119

■ About Idiopathic Thrombocytopenic Purpura (ITP)

ITP is a disease that causes serious bleeding events and bruising due to a decrease in platelet count below 100,000/ $\mu$ L, despite the absence of other obvious illnesses and medications that cause thrombocytopenia. ITP is classified into "acute ITP," in which the platelet count recovers normally within 6 months from the onset and "chronic ITP," in which thrombocytopenia continues for 6 months or more depending on the course of the medical condition. Fostamatinib is a treatment for chronic ITP.

The clinical symptoms of ITP include subcutaneous bleeding (petechiae or purpura) as well as bleeding from the gums or nose, blood in the urine or stool, and intracranial bleeding.

ITP is designated as an "intractable disease" by the Minister of Health, Labour and Welfare. The number of patients with ITP is estimated to be approximately 17,000\* and 2.16 per 100,000\*\* people are newly diagnosed with ITP every year in Japan. While the cause of ITP

has still not been definitively elucidated, it is believed that the platelet count is decreased as a result of the production of autoantibodies against platelets, leading to the destruction of platelets by macrophages in the spleen. ITP is currently treated with corticosteroids or thrombopoietin (TPO) receptor agonists as well as surgical removal of the spleen.

\*: Estimated based on the number of patients having certificates issued for specific disease treatment (designated intractable disease)

\*\*: Int J Hematol, 2011, 93: 329-35

#### ■About Fostamatinib

Tavalisse<sup>®</sup> (fostamatinib disodium hexahydrate), is an oral SYK inhibitor discovered by Rigel. It suppresses platelet destruction by macrophages and platelet depletion, thereby improving the bleeding symptoms caused by chronic idiopathic thrombocytopenic purpura (ITP).

The product has received orphan drug designation in the United States, Japan and South Korea. In the United States, the product obtained approval in 2018 for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment. Product approvals have followed in Europe, Canada, and the Middle East.

#### ■About Kissei Pharmaceutical Co., Ltd.

Under the management philosophy "contribute to society through high-quality, innovative pharmaceutical products" and "serve society through our employees", Kissei Pharmaceutical Co., Ltd. provides unique innovative pharmaceutical products as a drug discovery and R&D-oriented company for patients in the world with a special focus on urology, nephrology, dialysis, diabetes, gastroenterology, rare diseases and intractable disease.

For more details about Kissei Pharmaceutical Co., Ltd., please visit <https://www.kissei.co.jp/>

#### ■About Tai Tien Pharmaceuticals

Tai Tien Pharmaceuticals Co., Ltd was established in Taipei in 1987 and focuses on the field of lifestyle-related diseases with products such as HERBESSER<sup>®</sup>, CONCOR<sup>®</sup> (Japan name: Maintate<sup>®</sup>), LIVALO<sup>®</sup>, and CANAGLU<sup>®</sup>. In addition, Tai Tien is contributing to the treatment of patients with autoimmune diseases in Taiwan with the launches of SIMPONI<sup>®</sup> and REMICADE<sup>®</sup>.